Nurix therapeutics presents data from studies of its targeted protein degraders in b cell malignancies and initiates expansion of nx-2127 phase 1b trial in diffuse large b cell lymphoma and mantle cell lymphoma indications

Initiation of nx-2127 phase 1b expansion cohort in patients with diffuse large b cell lymphoma (dlbcl) was informed by a rapid and sustained complete response; phase 1b expansion cohort also initiated in patients with mantle cell lymphoma (mcl)
NRIX Ratings Summary
NRIX Quant Ranking